SCHEMBL7967987

SCHEMBL7967987

CNC(=O)c1ccc2c(c1F)CN(Cc1ccc(OC)cc1)C2=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.46
BRD4 O60885 1/20 0.43
HDAC6 Q9UBN7 2/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MMP1 P03956 1/20 0.40
MMP13 P45452 1/20 0.40
HDAC1 Q13547 2/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP2C19 P33261 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
CYP1A2 P05177 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7983771 0.90 IDH1 (0.48) IDH1HDAC6MEN1KMT2AMMP1
SCHEMBL7970258 0.90 IDH1 (0.44) IDH1HDAC6MEN1KMT2AMMP1
SCHEMBL1418449 0.89 IDH1 (0.47) IDH1HDAC6MEN1KMT2AMMP1
SCHEMBL7981153 0.89 IDH1 (0.48) IDH1HDAC6MMP1MMP13HDAC1
SCHEMBL7979545 0.80 BRD4 (0.45) IDH1BRD4HDAC6MEN1KMT2A
SCHEMBL12810295 0.79 MEN1 (0.39) IDH1MEN1KMT2AHDAC1ALDH1A1
SCHEMBL7977871 0.76 HDAC6 (0.49) BRD4HDAC6MEN1KMT2AHDAC1
SCHEMBL31159232 0.75 IDH1 (0.52) IDH1MEN1KMT2APOLBALDH1A1
SCHEMBL30908494 0.72 IDH1 (0.49) IDH1HDAC6MEN1KMT2AMMP1
SCHEMBL18786951 0.71 IDH1 (0.48) IDH1HDAC6MEN1KMT2AMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-8377923-B2 Triazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2013-02-19 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2011-05-05 US disclosed
EP-2298747-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2011-03-23 EP disclosed
WO-2010001946-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF アステラス製薬株式会社 (JP) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105460-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF HSD11B1, HSD11B2, HSD3B1 IDH1 235/4885BRD4 1594/4885HDAC6 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.